Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: drug manufacturers | Clear Filter
Summary:A letter from The White House, signed by Donald J. Trump and dated July 31, 2025, addresses AbbVie and other drug manufacturers, stating an Executive Order from May 12, 2025, aims to implement Most-Favored-Nation (MFN) drug pricing for American patients, demanding that US drug prices match those in other developed nations. The letter outlines specific demands for drug manufacturers, including extending MFN pricing to Medicaid, guaranteeing it for newly-launched drugs, repatriating foreign revenues, and participating in direct purchasing models, with a deadline for compliance by September 29, 2025, and a warning of further action if compliance is not met.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to deliver Most-Favored-Nation (MFN) prescription drug pricing to American patients.
- American brand name drug prices are up to three times higher than elsewhere, a result of 'global freeloading'.
- The Administration rejects policy changes that would result in 'billions of dollars in handouts to industry'.
- AbbVie and other drug manufacturers are called to extend MFN pricing to Medicaid for existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues generated abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Drug manufacturers should provide for Direct Purchasing at MFN pricing via Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) models.
- The Administration will 'deploy every tool in our arsenal' if drug manufacturers do not comply with the demands.
- Binding commitments to meet these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:The post presents a letter from The White House, signed by Donald Trump, addressed to EMD Serono, demanding that pharmaceutical manufacturers implement "Most-Favored-Nation" drug pricing for American patients by September 29, 2025, to significantly lower prescription drug costs and end perceived "global freeloading."
Sentiment:Directive
Key Claims:
- An Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" was signed on May 12, 2025, to ensure Americans pay the same drug prices as other developed nations.
- Brand name drug prices in the United States are up to three times higher than elsewhere.
- Pharmaceutical companies are called upon to extend Most-Favored-Nation (MFN) pricing to Medicaid for existing drugs.
- Pharmaceutical companies are called upon to guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues earned abroad by manufacturers must be repatriated to lower drug prices for American patients and taxpayers.
- Manufacturers must provide for direct purchasing at MFN pricing through Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) models.
- The Administration will deploy every tool in its arsenal to protect American families if manufacturers refuse to comply with demands.
- Binding commitments to these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:1/10
Potential Global Cross-Asset Impact:7/10
Summary:The White House, under Donald Trump, has issued a directive to AstraZeneca and all drug manufacturers to implement Most-Favored-Nation (MFN) drug pricing for American patients, aiming to stop other nations from "freeloading" on American innovation and to lower prescription drug costs significantly by September 29, 2025.
Sentiment:Directive/Demanding
Key Claims:
- Americans currently pay up to three times more for identical prescription drugs than patients in other developed nations.
- Other nations are "freeloading" on American innovation in drug development.
- An Executive Order on "Most-Favored-Nation Prescription Drug Pricing" was signed on May 12, 2025.
- Drug manufacturers are called upon to extend MFN pricing to Medicaid, guarantee MFN pricing for newly-launched drugs, return increased revenues from abroad to American patients, and offer direct purchasing at MFN prices.
- The Administration is prepared to use every tool to protect Americans from abusive drug pricing practices if cooperation is not met.
- Binding commitments for these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
« Previous
Page 1 of 1
Next »